Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

Victorian brain cancer researchers have achieved a global-first, using an innovative process to learn how a new drug ...

The participants will receive either 100 mg of verekitug every 12 weeks, 400 mg every 24 weeks, or a placebo, throughout 60 ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself.  | After ...

Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...

By Rishika Sadam and Bhanvi Satija (Reuters) -Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting ...

Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story ...